Brian Archbold compensation by year
Mesa Laboratories Summary Compensation Table · all 7 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
| Salary | $278,460 | $254,898 | $297,018 | $387,307 | $404,000 | $417,232 | $436,962 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $139,178 | $277,296 | $430,549 | $748,210 | $910,936 | $1,350,212 | $1,400,080 |
| Option awards | $138,023 | $182,482 | $260,064 | $226,725 | $198,042 | $0 | $0 |
| Non-equity incentive | $134,180 | $50,123 | $200,680 | $81,120 | $97,200 | $352,800 | $331,250 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $11,036 | $10,831 | $12,195 | $17,165 | $12,442 | $14,312 | $14,226 |
| Total | $700,877 | $775,630 | $1,200,506 | $1,460,527 | $1,622,620 | $2,134,556 | $2,182,518 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mesa Laboratories Inc DEF 14A filed July 22, 2026, accession 0000724004-26-000071, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Mesa Laboratories Inc filed document, accession 0000724004-26-000071. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 7,516 | $664,565 | — |
| RSU | 7,346 | $649,533 | — |
| RSU | 4,960 | $438,563 | — |
| PSU | 3,516 | $310,885 | — |
| PSU | 2,824 | $249,698 | — |
| RSU | 1,859 | $164,373 | — |
| RSU | 844 | $74,626 | — |
| Option | 1,511 | — | $131.67 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Mesa Laboratories Inc's FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Mesa Laboratories discloses, by trigger · FY2026| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,412,000 | $2,456,838 | $66,691 | $3,935,529 |
| Involuntary termination without cause | $706,000 | $721,777 | $66,691 | $1,494,468 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Mesa Laboratories Inc's FY2026 proxy. Estimates as the company printed them; a dash means it printed no figure.
Mesa Laboratories’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Gary Owens | Former CEO and President | $6,643,208 |
| John Sakys | VP and Chief Financial Officer | $2,471,543 |
| Brian Archbold · this page | SVP of Operations and Continuous Improvement | $2,182,518 |
The full Mesa Laboratories compensation record
free company briefThis page is one person within Mesa Laboratories's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Mesa Laboratories proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Mesa Laboratories's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mesa Laboratories's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MLAB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.